Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aqilion AB operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active for this portfolio. This action is being processed within 1 distinct art unit. The focus on Biotechnology & Pharmaceuticals indicates that the company's current intellectual property efforts are concentrated on biological or medicinal innovations.
Prosecution for the company involves a distinct examiner. LEE, WILLIAM Y is identified as the busiest examiner for the portfolio. This examiner is responsible for the pending office action. With only one examiner and one art unit involved in the pending workload, the company's current prosecution activity is concentrated within a specific technical area of the USPTO. This structure allows the applicant to focus on the examination style of LEE, WILLIAM Y, which can lead to a more consistent prosecution strategy for the 1 pending office action. The involvement of a single distinct examiner ensures that the prosecution strategy remains focused.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568249 | MACROCYCLIC TAK1 INHIBITORS | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568249 | MACROCYCLIC TAK1 INHIBITORS | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Dec 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAqilion AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Aqilion AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
